Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) | |
US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) | |
US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) |
Fluorescein Sodium And Benoxinate Hydrochloride is owned by Bausch Lomb Ireland.
Fluorescein Sodium And Benoxinate Hydrochloride contains Benoxinate Hydrochloride; Fluorescein Sodium.
Fluorescein Sodium And Benoxinate Hydrochloride has a total of 3 drug patents out of which 0 drug patents have expired.
Fluorescein Sodium And Benoxinate Hydrochloride was authorised for market use on 09 March, 2020.
Fluorescein Sodium And Benoxinate Hydrochloride is available in solution/drops;ophthalmic dosage forms.
Fluorescein Sodium And Benoxinate Hydrochloride can be used as ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic, procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic..
The generics of Fluorescein Sodium And Benoxinate Hydrochloride are possible to be released after 15 November, 2037.
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Market Authorisation Date: 09 March, 2020
Treatment: Procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic.; Ocular examination, intraocular pressure measurement, or removal of foreig...
Dosage: SOLUTION/DROPS;OPHTHALMIC